Active ingredient Adefovir dipivoxil interacts in the following cases:
The use of adefovir dipivoxil must be accompanied by the use of effective contraception.
There are limited data on the use of adefovir dipivoxil in pregnant women.
Studies in animals administered adefovir intravenously have shown reproductive toxicity. Studies in orally dosed animals do not indicate teratogenic or foetotoxic effects.
Adefovir dipivoxil is not recommended during pregnancy and in women of childbearing potential not using contraception. Adefovir dipivoxil should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
There are no data on the effect of adefovir dipivoxil on transmission of HBV from mother to infant. Therefore, the standard recommended procedures for immunisation of infants should be followed to prevent neonatal acquisition of HBV.
A risk to the newborns/infants cannot be excluded. It is recommended that mothers being treated with adefovir dipivoxil do not breast-feed their infants.
No human data on the effect of adefovir dipivoxil on fertility are available. Animal studies do not indicate harmful effects of adefovir dipivoxil on male and female fertility.
No studies on the effects on the ability to drive and use machines have been performed. However, based on the safety profile and mechanism of action, adefovir dipivoxil is expected to have no or negligible influence on these abilities.